EASD 2026: CagriSema weight loss holds at submaximal doses in REDEFINE-1 analysis
Data arrives as drugmakers race to bring successors to popular obesity therapies like semaglutide and tirzepatide to market.
Data arrives as drugmakers race to bring successors to popular obesity therapies like semaglutide and tirzepatide to market.